Autism spectrum disorder (ASD) affects an estimated 1 in 31 children in the United States by 2025, and prevalence in East Asian countries, such as South Korea, Singapore, and Japan, may be even higher than those in the United States. Despite its increasing prevalence, the underlying causes of ASD remain poorly understood, and there are currently no curative, preventive, or treatment options available.
A research team from POSTECH and ImmunoBiome in Korea, led by Professor Sin-Hyeog Im, who also serves as the CEO of ImmunoBiome, has made a groundbreaking discovery that reveals a multi-faceted mechanism behind ASD. This study, published in the July issue of Nature Communications (vol. 16, 6422), in collaboration with Dr. John C. Park and Prof. Tae-Kyung Kim, demonstrates that the gut microbiota and host immune system together can influence the progression of ASD in a genetic mouse model.
ASD has long been regarded as a genetically driven disorder. However, growing evidence suggests that environmental and microbial factors also play a role. The human gut harbors more than ten times as many microbial cells as human cells, and these microbes play vital roles in metabolism and the development of the immune system.
In recent years, clinical studies have shown that individuals with ASD have distinct gut microbiota compositions compared to neurotypical controls. Moreover, gastrointestinal comorbidities affect up to 90% of ASD patients, pointing to a potential pathogenic role of gut dysbiosis in ASD. These findings have contributed to the growing gut–brain axis hypothesis, which proposes that gut microbes can influence brain function.
To investigate this further, Prof. Im’s team generated the world’s first germ-free (GF) genetic mouse (BTBR) model for ASD, allowing them to dissect the effects of host genetics, gut microbiota composition, metabolites, and host immune response on ASD progression. Remarkably, GF-ASD mice lacking gut microbiota showed reduced ASD-associated behaviors, suggesting that the gut microbiota, rather than host genetics, may be the dominant driver of ASD symptoms.
Additionally, GF-ASD mice exhibited reduced neuroinflammation, particularly in inflammatory microglia and a newly identified brain-resident T cell population. By depleting T cells, the researchers were able to prevent ASD-like phenotypes, highlighting a gut-immune-brain signaling pathway in ASD pathology.
Using 16S-rRNA sequencing and a large-scale metabolomics approach, the researchers found that the gut microbiota influences the balance between glutamate and GABA, two key neurotransmitters that are excitatory and inhibitory, respectively. An altered glutamate/GABA ratio may directly affect neuronal activity and behavior in ASD.
To address this imbalance, ImmunoBiome’s AI team developed an in silico model to predict probiotic strains with specific metabolic functions. One such strain, Limosilactobacillus reuteri IMB015, was identified for its ability to uptake glutamate and produce GABA. In ASD mouse models, treatment with IMB015 restored metabolic balance, reduced neuroinflammation, and ameliorated behavioral abnormalities.
ImmunoBiome plans to advance L. reuteri IMB015 as a live biotherapeutic product (LBP) or probiotics for ASD treatment. This includes conducting comprehensive preclinical toxicity evaluations and progressing to clinical trials to assess its safety and therapeutic efficacy in humans.
ImmunoBiome is a leading biotechnology company based in Korea, specializing in the development of Live Biotherapeutic Products (LBPs) for intractable diseases, including cancer, autoimmune disorders, and neurodevelopmental conditions. Through its proprietary Avatiome™ platform, ImmunoBiome develops and rationally selects pharmacologically active bacterial strains, characterizes their immunological mechanisms, and builds therapeutic pipelines based on microbial-derived molecules.
The company maintains a comprehensive database of human commensal bacteria isolated from mucosal surfaces and collaborates closely with POSTECH and global research partners. By integrating AI-based analytics, immune profiling, and microbiome science, ImmunoBiome is pioneering precision microbiome-based therapies and consumer products that aim to modulate host health through the gut–immune–brain axis.
Reference: Park JC, Sim MA, Lee C, et al. Gut microbiota and brain-resident CD4+ T cells shape behavioral outcomes in autism spectrum disorder. Nat Commun. 2025;16(1):6422. doi: 10.1038/s41467-025-61544-0
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.